Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Myelin oligodendrocyte glycoprotein
antibody-associated disease (MOGAD) is an immune-mediated demyelinating
disorder that affects the central nervous system by causing inflammation and
damage to the optic nerve, spinal cord, brain, and/or brainstem. The MOG
protein is found in the nerve coverings of the central nervous system and is
involved in myelin maturation and cell surface interactions. The exact cause of
MOGAD is unknown, and it affects males and females equally but is more
prevalent in children than adults. The symptoms of MOGAD are categorized into
optic neuritis, transverse myelitis, acute disseminated encephalomyelitis
(ADEM), and cerebral encephalitis. Diagnosing MOGAD requires a blood test to
screen for antibodies and MRI and lumbar puncture.
·
In the USA, the estimated incidence of MOGAD
is 1 to 2 per 100,000 individuals annually.
Thelansis’s “Myelin Oligodendrocyte
Glycoprotein Antibody-associated Disease (MOGAD) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2022 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Myelin
Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
across 8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Myelin Oligodendrocyte Glycoprotein
Antibody-associated Disease (MOGAD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech business
environment to provide an optimized support system to all levels of the
decision-making process. It enables business leaders in forward-thinking and
proactive decision-making. Thelansis supports scientific and commercial teams
in seamless CI support by creating an AI/ ML-based technology-driven platform
that manages the data flow from primary and secondary sources.
Comments
Post a Comment